Synthetic cell platforms and methods of use thereof

• US 8,501,905 B2
• Filed: 03/21/2008
• Issued: 08/06/2013
• Est. Priority Date: 03/22/2007
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Schaffer, David V., Healy, Kevin Edward, Little, Lauren, Daugherty, Patrick Sean
• Primary Examiner(s): NAVARRO, ALBERT MARK
• Application Number:
  US12/532,098
• Publication Number:
  US 20100189760A1
• Time in Patent Office: 1,964 Days
• Field of Search: None
• US Class Current: 530/300
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 17/00 Carrier-bound or immobilised peptides carrier-bound or immobilised enzymes C12N11/00; Preparation thereof
• CPC Class Codes: C12N 2500/99 Serum-free medium
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2533/50 Proteins
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: G01N 33/5073 Stem cells
• CPC Class Codes: G01N 33/542 with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

The present invention provides synthetic cell platforms. The synthetic cell platforms can be used for culturing cells in vitro. The synthetic cell platforms can also be implanted together with bound cells into an individual. The present invention provides methods of using the platforms to provide cells or progeny of such cells for use in various applications, including clinical applications; and methods of use of the platforms to introduce cells into an individual.

Claims

1. A synthetic cell platform comprising:

a) a synthetic substrate; and

b) a mammalian stem cell-binding peptide covalently linked to the synthetic substrate, wherein the stem cell binding peptide has a length of up to about 50 amino acids, and wherein the stem cell binding peptide comprises the amino acid sequence SEQ ID NO;

22.

2. The synthetic cell platform of claim 1, wherein the stem cell-binding peptide is covalently linked to the synthetic substrate at a density of from about 0.1 pmol/cm² to about 100 pmol/cm².

3. The synthetic cell platform of claim 1, wherein the stem cell-binding peptide is covalently linked to the synthetic substrate at a density of from about 1 pmol/cm² to about 25 pmol/cm².

4. The synthetic cell platform of claim 1, wherein the synthetic substrate is an interpenetrating polymer network, a synthetic hydrogel, a semi-interpenetrating polymer network, or a thermo-responsive polymer.

5. The synthetic cell platform of claim 1, wherein the synthetic substrate comprises a co-polymer of polyacrylamide and poly(ethylene glycol).

6. The synthetic cell platform of claim 1, wherein the stem cell is an embryonic stem cell, a neural stem cell, a hematopoietic stem cell, a mesenchymal stem cell, or an induced pluripotent stem cell.

7. The synthetic cell platform of claim 1, further comprising a mammalian stem cell bound to the peptide.